论文部分内容阅读
据《N Engal J Med》2001年345卷第13期报道 吸入糖皮质激素是气喘病人长期治疗最常用的药物,但对长期吸入糖皮质激素治疗是否会像口服糖皮质激素治疗那样会降低骨密度则仍有争议。在一项3年的前瞻性研究中,美国波士顿市Brigham和妇女医院Elliot Israel博士等,对绝经前妇女吸入糖皮质激素剂量与骨质丢失速率之间的相关性进行了验证。研究对象为患有气喘的109名绝经前妇女,其年龄为18～45岁,无任何已知可引起骨质丢失的其他情况,接受使用吸入性曲安奈德(100μg/喷)治疗。应用双光子吸收测量仪在基线及治疗后0.5、1、2、3年测定骨密度。定期测定血清
According to N Engal J Med 2001, Volume 345, Issue 13 Inhaled glucocorticoid is the most commonly used drug for long-term treatment of asthmatic patients, but whether long-term inhaled glucocorticoid therapy reduces bone mineral density like oral glucocorticoid treatment It is still controversial. In a 3-year prospective study, Brigham and Womens Hospital, Elliot Israel, Ph.D., Boston, USA, etc., examined the correlation between the dose of glucocorticosteroid inhaled and the rate of bone loss in premenopausal women. The study involved 109 premenopausal women with asthma who were 18-45 years old and did not have any other conditions known to cause bone loss and were treated with inhaled triamcinolone acetonide (100 μg / spray). Two-photon absorption measurements were used to determine the bone mineral density at baseline, 0.5, 1, 2, and 3 years after treatment. Serum was measured regularly